3 Fermentation Based Ingredients Maker, Active Ingredients and Contract Research Company and OTC Medicines Producer Stocks With a Strong Future Roadmap: Concord Biotech, Laurus Labs and Marksans Pharma
- October 26, 2026
- Posted by: Ankit Jaiswal
- Category: Best Stocks
Concord Biotech, Laurus Labs and Marksans Pharma: ROE of 12.9% to 16.8% and FY22 to FY26 revenue CAGR of 8.5% to 18.6%. Prices as of 23 Oct 2026.
Quick Answer
The three fermentation API, contract pharma and OTC stocks to watch are Concord Biotech, Laurus Labs and Marksans Pharma. Their return on equity ranges from 12.9% to 16.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.5% to 18.6%. Laurus Labs has the highest return on equity at 16.8%, while Marksans Pharma has the fastest revenue growth at 18.6% a year. Prices are based on the 23 October 2026 close, and this article is educational, not investment advice.
Fermentation API, contract pharma and OTC stocks give investors a way to track businesses that sit close to everyday demand in India. Concord Biotech, Laurus Labs and Marksans Pharma cover a fermentation based ingredients maker, an active ingredients and contract research company and an OTC medicines producer.
This list covers three fermentation API, contract pharma and OTC stocks with complete current figures: Concord Biotech, Laurus Labs and Marksans Pharma. Every figure comes from the latest reported financials and the 23 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Fermentation API, Contract Pharma and OTC Stocks?
Fermentation API, contract pharma and OTC stocks are listed drug makers that supply fermentation based and chemical ingredients, contract development and over the counter medicines. Their earnings depend on global orders, approvals, capacity use and input costs.
Fermentation API, Contract Pharma and OTC Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Concord Biotech | 1,229.3 | 13,421 | 49.2 | 36.0 | 12.9 | 0.00 |
| Laurus Labs | 1,970 | 111,434 | 102.2 | 36.0 | 16.8 | 0.48 |
| Marksans Pharma | 286.9 | 12,994 | 24.9 | 35.7 | 13.8 | 0.11 |
On valuation, Marksans Pharma trades at a P/E below the industry P/E, while Concord Biotech and Laurus Labs trade above it, which reflects the growth the market already expects. Readers comparing fermentation API, contract pharma and OTC stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Fermentation API, Contract Pharma and OTC Stocks Have a Strong Roadmap in India?
Fermentation API, contract pharma and OTC stocks have a strong roadmap in India because global buyers add dependable ingredient suppliers and outsourced development and over the counter sales keep widening the market.
- Ingredient supply. Global drug makers add Indian suppliers.
- Contract work. Outsourced development brings repeat orders.
- Over the counter sales. Self care medicines sell in many markets.
Why Concord Biotech Features Among These Fermentation API, Contract Pharma and OTC Stocks
Among the fermentation API, contract pharma and OTC stocks on this list, Concord Biotech is a Gujarat-based biopharma company that makes fermentation-based active ingredients such as immunosuppressants, oncology drugs and anti-infectives for global pharma customers.
The company has a return on equity of 12.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 13,421 crore. The stock trades at a P/E of 49.2, above the industry P/E of 36.0.
Revenue rose from Rs 736 crore in FY22 to Rs 1,107 crore in FY26, a compound annual growth rate of 10.7%. Net profit grew from Rs 175 crore in FY22 to Rs 259 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 24.2% year on year to Rs 270 crore, while net profit rose 31.0% to Rs 57.7 crore.
Roadmap: The company is among the leading global suppliers in its key immunosuppressant molecules and is moving into formulations and new fermentation products. Its backward integration and regulatory approvals support its position.
What to watch: Monitor the pace of new product introductions and the contribution from formulations.
Why Laurus Labs Features Among These Fermentation API, Contract Pharma and OTC Stocks
Among the fermentation based ingredient shares on this list, Laurus Labs is a Hyderabad-based pharmaceutical company with businesses in active ingredients, finished formulations, custom synthesis and biotechnology, with a leading position in anti-retroviral medicines.
Revenue rose from Rs 4,951 crore in FY22 to Rs 6,868 crore in FY26, a compound annual growth rate of 8.5%. Net profit for FY26 was Rs 890 crore, a net margin of 13.0%.
In the June 2026 quarter, revenue grew 28.8% year on year to Rs 2,035 crore, while net profit rose 124.7% to Rs 362 crore. The company has a return on equity of 16.8%, a debt to equity ratio of 0.48 and a market capitalisation of Rs 111,434 crore. The stock trades at a P/E of 102.2, above the industry P/E of 36.0.
Roadmap: The company has widened its range from anti-retroviral ingredients into oncology, cardiac and other therapies and has added capacity in formulations. Its custom synthesis and biotechnology arms add exposure to services for global drug developers.
What to watch: Follow the ramp-up of new capacity in formulations and the order flow in custom synthesis.
Why Marksans Pharma Features Among These Fermentation API, Contract Pharma and OTC Stocks
Among the three companies on this list, Marksans Pharma is a Mumbai-based drug maker that produces over-the-counter and prescription formulations at plants in India and sells them in the United Kingdom, the United States, Australia and other markets.
In the June 2026 quarter, revenue grew 38.5% year on year to Rs 866 crore. Revenue rose from Rs 1,533 crore in FY22 to Rs 3,033 crore in FY26, a compound annual growth rate of 18.6%.
Net profit grew from Rs 187 crore in FY22 to Rs 420 crore in FY26, which works out to a compound annual growth rate of 22.5%. The company has a return on equity of 13.8%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 12,994 crore. The stock trades at a P/E of 24.9, below the industry P/E of 35.7.
Roadmap: The company is adding capacity and new products for regulated markets, which supports export growth. A focus on over-the-counter products gives it steady, repeat demand.
What to watch: Track export growth, new product approvals and plant utilisation.
Concord Biotech vs Laurus Labs vs Marksans Pharma on Key Financials
The table below sets the three fermentation API, contract pharma and OTC stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Concord Biotech | 736 | 1,107 | 10.7% | 259 | 23.4% |
| Laurus Labs | 4,951 | 6,868 | 8.5% | 890 | 13.0% |
| Marksans Pharma | 1,533 | 3,033 | 18.6% | 420 | 13.8% |
Laurus Labs posts the highest return on equity in this group at 16.8%. Laurus Labs has the largest FY26 revenue at Rs 6,868 crore, and Marksans Pharma shows the fastest revenue growth with a 18.6% compound annual rate. A useful habit with fermentation API, contract pharma and OTC stocks is to check each new quarterly result against the capacity plans the company described earlier.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Concord Biotech | 218 | 270 | 24.2% |
| Laurus Labs | 1,580 | 2,035 | 28.8% |
| Marksans Pharma | 626 | 866 | 38.5% |
Key Risks to Check Before Investing in Fermentation API, Contract Pharma and OTC Stocks
Every theme carries risks that deserve a check before any decision. For these fermentation API, contract pharma and OTC stocks, the main points are: Long-term fermentation based ingredient shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory checks. Plant inspections can affect approvals.
- Order timing. Large contracts can shift between periods.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter fermentation API, contract pharma and OTC stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Fermentation API, Contract Pharma and OTC Stocks
Fermentation API, contract pharma and OTC stocks work best when investors track growth, valuation and return on equity side by side. Concord Biotech, Laurus Labs and Marksans Pharma each have a clear plan to grow. Based on the 23 October 2026 close, Concord Biotech trades at Rs 1,229.3, Laurus Labs at Rs 1,970 and Marksans Pharma at Rs 286.9. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these fermentation API, contract pharma and OTC stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track fermentation API, contract pharma and OTC stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are fermentation API, contract pharma and OTC stocks?
Ans. Fermentation API, contract pharma and OTC stocks are listed drug makers that supply fermentation based and chemical ingredients, contract development and over the counter medicines. Their earnings depend on global orders, approvals, capacity use and input costs. This list looks at three of them, Concord Biotech, Laurus Labs and Marksans Pharma, using reported FY22 to FY26 financials and the 23 October 2026 closing prices.
Which fermentation API, contract pharma and OTC stocks are covered in this list?
Ans. This list covers Concord Biotech, Laurus Labs and Marksans Pharma. Based on the 23 October 2026 close, Concord Biotech traded at Rs 1,229.3, Laurus Labs at Rs 1,970 and Marksans Pharma at Rs 286.9. Their return on equity ranges from 12.9% to 16.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.5% to 18.6%.
Why do fermentation API, contract pharma and OTC stocks have a strong future roadmap in India?
Ans. Fermentation API, contract pharma and OTC stocks have a strong roadmap in India because global buyers add dependable ingredient suppliers and outsourced development and over the counter sales keep widening the market. The main drivers are as follows. Ingredient supply. Global drug makers add Indian suppliers. Contract work. Outsourced development brings repeat orders. Over the counter sales. Self care medicines sell in many markets. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Concord Biotech performed financially?
Ans. Revenue rose from Rs 736 crore in FY22 to Rs 1,107 crore in FY26, a compound annual growth rate of 10.7%. Net profit grew from Rs 175 crore in FY22 to Rs 259 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 24.2% year on year to Rs 270 crore, while net profit rose 31.0% to Rs 57.7 crore. The company has a return on equity of 12.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 13,421 crore. The stock trades at a P/E of 49.2, above the industry P/E of 36.0. Looking ahead, the company is among the leading global suppliers in its key immunosuppressant molecules and is moving into formulations and new fermentation products. Its backward integration and regulatory approvals support its position.
How has Laurus Labs performed financially?
Ans. Revenue rose from Rs 4,951 crore in FY22 to Rs 6,868 crore in FY26, a compound annual growth rate of 8.5%. Net profit for FY26 was Rs 890 crore, a net margin of 13.0%. In the June 2026 quarter, revenue grew 28.8% year on year to Rs 2,035 crore, while net profit rose 124.7% to Rs 362 crore. The company has a return on equity of 16.8%, a debt to equity ratio of 0.48 and a market capitalisation of Rs 111,434 crore. The stock trades at a P/E of 102.2, above the industry P/E of 36.0. Looking ahead, the company has widened its range from anti-retroviral ingredients into oncology, cardiac and other therapies and has added capacity in formulations. Its custom synthesis and biotechnology arms add exposure to services for global drug developers.
How has Marksans Pharma performed financially?
Ans. Revenue rose from Rs 1,533 crore in FY22 to Rs 3,033 crore in FY26, a compound annual growth rate of 18.6%. Net profit grew from Rs 187 crore in FY22 to Rs 420 crore in FY26, which works out to a compound annual growth rate of 22.5%. In the June 2026 quarter, revenue grew 38.5% year on year to Rs 866 crore. The company has a return on equity of 13.8%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 12,994 crore. The stock trades at a P/E of 24.9, below the industry P/E of 35.7. Looking ahead, the company is adding capacity and new products for regulated markets, which supports export growth. A focus on over-the-counter products gives it steady, repeat demand.
What risks should investors check before buying fermentation API, contract pharma and OTC stocks?
Ans. Investors should check a few risks before buying fermentation API, contract pharma and OTC stocks. Regulatory checks. Plant inspections can affect approvals. Order timing. Large contracts can shift between periods. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of fermentation API, contract pharma and OTC stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 23 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
